European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
|
|
|
Advancements in Genealogy
The DNA of a New Industry
Futura Genetics’ Efi Binder delves into the rapidly progressing field of genome sequencing, expanding on the decreasing costs that are associated with this type of testing.
|
|
|
|
|
|
Leveraging Automated Discovery Platforms
Easy as ADC
Dr Xin Liu at Sphere Fluidics emphasises the efficacy and reduced toxicities of novel antibody-drug conjugates as a promising yet costly means to treating life-limiting diseases.
|
|
|
|
Analytical Techniques in Therapeutics
ADC Characterisation
Christopher M Bianchetti PhD, Henry J Parker, Katherine C Hanson PhD, and Stephen Gacheru PhD at PPD Laboratories illustrate how monoclonal antibody-based therapeutics are advancing cancer treatment.
|
|
|
|
Antibody-Drug Conjugates in Chemotherapy
The ADC Jigsaw
Antibody-drug conjugates are good contenders in the fight against cancer. Dr Jenny Thirlway at Iksuda outlines how this route of cancer treatment is more effective in eradicating cancer cells and reducing side effects.
|
|
|
|
|
Choosing the Right Biomaterial
A View from the Bench
Barbara Vanhoecke at Rousselot investigates the possibility of removing endotoxins that have proven to be a hindrance in instances where using gelatin would be preferable.
|
|
|
|
The Cancer Problem
Closer to the Cure
Christian Rommel at Roche advises companies to refrain from treating every step forward in cancer research as a potential cure. Rather, scientists should accept that finding a cure will be a more difficult journey than anticipated.
|
|
|
|
Immunoncology Drug Development
Do More With Less
Dr Katie Chapple at Sartorius Stedim Biotech and Andrea Gomez-Donart at IntelliCyt outline the current advances in immunoncology, looking specifically at drugs that harness the immune system.
|
|
|
|
Antibiotic Resistance
Fighting the Global Threat
DAs antibiotic resistance continues to plague the healthcare industry, Adrian Fellows at AGA Nanotech urges companies to unite and educate
|
|
|
|
Achieving the Full Potential of Immunoncology
Leveraging Novel Therapeutics and Diagnostic Assays
Marisa Pearce at Molecular MD, an ICON company, argues that, although immunotherapy is nothing new, it has much untapped potential yet to be explored.
|
|
|
|
Translational Safety
The Next Frontier
InSphero’s Judi Wardwell, Dr Radina Kostadinova, and Professor Armin Wolf believe in vitro tissue models to be the way forward in reducing attrition rates of drug candidates, ultimately improving patient safety and return on investment.
|
|
|
|
Fermenting Peptides and Proteins
The Renaissance of Microbial Fermentation
The advent of cell culture systems ultimately led to increased interest of microbial-produced biopharmaceuticals, as told by Dr Vladas Bumelis at Northway Biotechpharma.
|
|
|
|
|
AI and Multifactorial Data Analytics
A New Lens
Analytical tools are necessary for understanding the architecture of multifactorial diseases. Steve Gardner at RowAnalytics introduces the new generation of artificial intelligence and data analytics that can aid in the untangling of disease risk.
|
|
|
|
Examining Process Residuals
Mass Spectrometric Analysis of Process-Related Impurities
Dr Richard L Easton and Dr Andrew J Reason at BioPharmaSpec demonstrate why mass spectrometry is a highly versatile tool for residual detection, even in the most complex of mixtures.
|
|
|
|
|
Systems Medicine and Drug Repurposing
An Answerable Challenge
Neurodegeneration and neurological disorders as a whole could be considered as the main cause of disability-adjusted years. Dr Hermann Mucke at H.M. Pharma Consultancy encourages the exploration of new drug combinations to drive treatment of such diseases.
|
|
|
|
Targeting Aβ Oligomers
The Future of R&D in Alzheimer’s Disease
Dr Neil Cashman and Dr James W Kupiec at ProMIS Neurosciences explain the ways in which new investigational drugs are transforming clinical trial design and the R&D landscape.
|
|
|
|
|
In Brief
Great Expectations
EBR’s Industry Advisor Emile Bellott reviews rare disease progress in the biopharmaceutical arena.
|
|
|
|
Immunology
The Factory for Next- Generation Therapies
EBR’s Editor Dr Deborah O’Neil recounts the themes of the issue, warning of the dangers of antimicrobial resistance while celebrating advancements in personal genetic data.
|
|
|
|
|
|
